Researcher Profile

Researcher Profile

Nelson Shu-Sang Yee, MD, PhD, RPh

Nelson Shu-Sang Yee, MD, PhD, RPh

Associate Professor, Department of Medicine
Division of Hematology and Oncology
Assistant Professor, Department of Medicine
Scientific Program:Next-Generation Therapies
Disease Teams:
Gastrointestinal Cancer
Liver, Pancreas and Foregut Cancer

Research Interests

  • Therapeutics
  • Neoplasms
  • Pancreatic Neoplasms
  • Adenocarcinoma
  • Zebrafish
  • Biomarkers
  • Ion Channels
  • Carcinoma
  • Mast Cells
  • Growth
  • Exocrine Pancreas
  • Hepatocellular Carcinoma

Clinical Trials

CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts: a prospective, randomized, double-blind, multi-center clinical trial
A Phase II Study to Evaluate the Response and Tolerability of Verzenio(Abemaciclib) in Patients with Advanced Biliary Tract Carcinoma who have Failed Prior Chemotherapy
A Phase II Study to Evaluate the Efficacy of Nanoliposomal Irinotecan in Combination with Oxaliplatin, Leucovorin, and 5-Fuorouracil for Patients with Locally Advanced Pancreatic Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI15-067
Micro/nano technology for extracellular vesicle isolation and towards non-invasive pancreatic cancer diagnosis
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
A Phase III Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012)(LEAP-012)
A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C mutation (MRT849-001)
CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer
EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
Risk Factors for CIPN Following an Oxaliplatin-Containing Chemotherapy Regimen in Colorectal Cancer Patients

Recent Publications


Mohamed, A, Menon, H, Chulkina, M, Yee, NS & Pinchuk, IV 2021, 'Drug–microbiota interaction in colon cancer therapy: Impact of antibiotics', Biomedicines, vol. 9, no. 3, 259, pp. 1-13.


Wheelden, M & Yee, NS 2020, 'Clinical evaluation of the safety and efficacy of trifluridine/tipiracil in the treatment of advanced gastric/gastroesophageal junction adenocarcinoma: Evidence to date', OncoTargets and Therapy, vol. 13, pp. 7459-7465.
Yee, NS, Zhang, S, He, HZ & Zheng, SY 2020, 'Extracellular vesicles as potential biomarkers for early detection and diagnosis of pancreatic cancer', Biomedicines, vol. 8, no. 12, 581, pp. 1-20.
Yee, NS 2020, 'Liquid biopsy: A biomarker-driven tool towards precision oncology', Journal of Clinical Medicine, vol. 9, no. 8, 2556, pp. 1-3.
Schmitz, KH, Potiaumpai, M, Schleicher, EA, Wolf, LJ, Doerksen, SE, Drabick, JJ, Yee, NS, Truica, CI, Mohamed, AA, Shaw, BW & Farley, DC 2021, 'The exercise in all chemotherapy trial', Cancer, vol. 127, no. 9, pp. 1507-1516.
Shen, C, Thornton, JD, Newport, K, Schaefer, E, Zhou, S, Yee, NS, Dodge, D & Leslie, D 2020, 'Trends and patterns in the use of opioids among metastatic breast cancer patients', Scientific reports, vol. 10, no. 1, 21698.


Willumsen, N, Ali, SM, Leitzel, K, Drabick, JJ, Yee, N, Polimera, HV, Nagabhairu, V, Krecko, L, Ali, A, Maddukuri, A, Moku, P, Ali, A, Poulose, J, Menon, H, Pancholy, N, Costa, L, Karsdal, MA & Lipton, A 2019, 'Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer', Scientific reports, vol. 9, no. 1, 19761.
on behalf of the RELIVE Investigators 2019, 'Correction to (The Lancet Gastroenterology & Hepatology (2019) 4(6) (454–465), (S2468125319300408), (10.1016/S2468-1253(19)30040-8))', The Lancet Gastroenterology and Hepatology, vol. 4, no. 7, pp. e6.
Merle, P, Blanc, JF, Phelip, JM, Pelletier, G, Bronowicki, JP, Touchefeu, Y, Pageaux, G, Gerolami, R, Habersetzer, F, Nguyen-Khac, E, Casadei-Gardini, A, Borbath, I, Tran, A, Wege, H, Saad, AS, Colombo, M, Abergel, A, Richou, C, Waked, I, Yee, NS, Molé, A, Attali, P, Le Boulicaut, J, Vasseur, B, Moussata, D, Grangé, JD, Ratziu, V, Khemissa-Akouz, F, Regnault, H, Dauvois, B, Zarski, JP, Ollivier-Hourmand, I, Manfredi, S, Debette-Gratien, M, Gangloff, A, Fontanges, T, Baron, A, Bouattour, M, Vincent, J, Sieghart, W, Maieron, A, Peeters, M, Delwaide, J, Lasser, L, Berg, T, Schultheiß, M, Zipprich, A, Trojan, J, Ehmer, U, Luppi, G, Luca, G, Tamberi, S, Amoroso, D, Alabiso, O, Buonadonna, A, Toniutto, P, Tamburini, E, Cubillo, A, Muñoz, A, Guillén, C, Sánchez, G, Manzano, H, Navarro, V, Ales, I, Massuti, B, Dank, M, Bodoky, G, Kahan, Z, Horváth, Z, Gabrail, N, Ozer, H, Galanopoulos, C, Hauke, R, Raj, M, Harputluoglu, H, Sevinc, A, Goker, E, Coker, A, Yalcin, S, Ali, M, Ata, O, Tugba, I, ElKassas, M, Abdel, A, Wakid, I, Shamaa, S, El, N, Kohail, H, Makarem, J, Chehade, I, Farhat, F, López, C & Marín, M 2019, 'Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial', The Lancet Gastroenterology and Hepatology, vol. 4, no. 6, pp. 454-465.
Wan, Y, Maurer, M, He, HZ, Xia, YQ, Zhang, WL, Hao, SJ, Yee, NS & Zheng, SY 2019, Enrichment of Extracellular Vesicles Via Lipid Nanoprobe-Functionalized Nanostructured Silica Microdevice. in 2019 20th International Conference on Solid-State Sensors, Actuators and Microsystems and Eurosensors XXXIII, TRANSDUCERS 2019 and EUROSENSORS XXXIII., 8808761, 2019 20th International Conference on Solid-State Sensors, Actuators and Microsystems and Eurosensors XXXIII, TRANSDUCERS 2019 and EUROSENSORS XXXIII, Institute of Electrical and Electronics Engineers Inc., pp. 273-276, 20th International Conference on Solid-State Sensors, Actuators and Microsystems and Eurosensors XXXIII, TRANSDUCERS 2019 and EUROSENSORS XXXIII, Berlin, Germany, 6/23/19.
Wan, Y, Maurer, M, He, HZ, Xia, YQ, Hao, SJ, Zhang, WL, Yee, NS & Zheng, SY 2019, 'Enrichment of extracellular vesicles with lipid nanoprobe functionalized nanostructured silica', Lab on a Chip, vol. 19, no. 14, pp. 2346-2355.
Yee, NS & Lee, NP 2019, 'Special issue: Cancer biomarkers and targets in digestive organs', Biomedicines, vol. 7, no. 1, 3.


Pishvaian, MJ, Weiss, GJ, Falchook, GS, Yee, N, Gil-Martin, M, Shahda, S, Moreno, V, Brana, I, Crittenden, M, Formenti, S, Al-Rajabi, R, Papadopoulos, KP, Stankevich, E, Feng, M, Li, J, Mathias, M, Kroog, G, Lowy, I & Fury, MG 2018, 'Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a phase I study', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii410.
Yee, NS, Lengerich, EJ, Schmitz, KH, Maranki, JL, Gusani, NJ, Tchelebi, L, Mackley, HB, Krok, KL, Baker, MJ, de Boer, C & Yee, JD 2018, 'Frontiers in gastrointestinal oncology: Advances in multi-disciplinary patient care', Biomedicines, vol. 6, no. 2, 64.
Fonkoua, LK & Yee, NS 2018, 'Molecular characterization of gastric carcinoma: Therapeutic implications for biomarkers and targets', Biomedicines, vol. 6, no. 1, 32.
Posadas, K, Ankola, A, Yang, Z & Yee, NS 2018, 'Tumor molecular profiling for an individualized approach to the treatment of hepatocellular carcinoma: A patient case study', Biomedicines, vol. 6, no. 2, 46.
Yee, NS 2018, 'Update in systemic and targeted therapies in gastrointestinal oncology', Biomedicines, vol. 6, no. 1, 34.

Clinical Trials Search

Children (age < 18 years)
Adults (age >= 18 years)